Clinical Trials on AMH in United Kingdom

Total 405 results

Oraya Therapeutics, Inc.

Withdrawn

Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)

Macular Degeneration | Age-related Macular Degeneration | AMD | Wet AMD | Wet Age-related Macular Degeneration

United Kingdom, Italy
Moorfields Eye Hospital NHS Foundation Trust
King's College London; Cardiff University; University College, London; Newcastle... and other collaborators

Recruiting

Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners (FENETRE)

AMD

United Kingdom
Clavis Pharma
Syneos Health; Theradex; CardiaBase; Learn & Confirm

Completed

The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)

Relapsed/Refractory AML

United Kingdom, Spain
Newtricious R&D BV
Sprim Advanced Life Sciences

Completed

Intervention Trial in Early Age-related Macular Degeneration (I-TEAM)

Age-related Macular Degeneration (AMD)

United States, Germany, Netherlands, United Kingdom
H Scott Boswell
Takeda

Terminated

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

AML | AML, Adult

United States
University of Birmingham

Completed

A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) (PARC)

Cancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AML

United Kingdom, Australia, Netherlands
Moorfields Eye Hospital NHS Foundation Trust

Completed

Dual Wavelength OCT

Retinal Degeneration | Diabetic Retinopathy | Retinal Dystrophies | AMD

United Kingdom
Reproductive Medicine Associates of New Jersey
Merck Sharp & Dohme LLC; Organon

Completed

Evaluation of Anti-mullerian Hormone Levels as Predictive of IVF Outcomes in Women Over 38 Years Old

AMH Levels | Inhibin B Levels | IVF Patients Over 38 Years Old

United States
Alcon Research

Completed

Anecortave Acetate Versus Placebo in AMD Patients Following PDT

AMD

United States
Etan Orgel
Astellas Pharma Global Development, Inc.

No longer available

Individual Patient Expanded Access Gilteritinib (ASP2215)

AML

United States
Cell Medica Ltd
University College, London; Cell Therapy Catapult

Completed

A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

United Kingdom, Germany, Belgium
M.D. Anderson Cancer Center

Recruiting

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

AML | MDS

United States
Retina Institute of Hawaii

Completed

Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Wet AMD

United States
VisionCare, Inc.

Recruiting

Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

Age-Related Macular Degeneration | AMD

Italy, Ireland, Spain, Germany, United Kingdom
Oraya Therapeutics, Inc.

Completed

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD (INTREPID)

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Diseases | AMD | Wet AMD | Wet Age-Related Macular Degeneration

United Kingdom, Czech Republic, Austria, Germany, Italy
Montefiore Medical Center

Recruiting

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

AML | MDS

United States
Alcon Research

Terminated

Anecortave Acetate Risk-Reduction Trial (AART)

Dry AMD

United States
Abramson Cancer Center at Penn Medicine
Bristol-Myers Squibb

Recruiting

Assessment of Geriatric Evaluations Impact on New AML Guidance (AGE-ING)

AML, Adult

United States
David Iberri

Terminated

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults | AML (Adult) With 11q23 (MLL) Abnormalities | AML (Adult) With Del (5q) | AML (Adult) With Inv (16) (p13; q22) | AML (Adult) With t (16;16) (p13; q22) | AML (Adult) With t (8; 21) (q22; q22) and other conditions

United States
Pfizer

Terminated

A Study Of Early Markers Of Choroidal Neovascularization

Age-related Macular Degeneration (AMD) | Choroidal Neovascularization (CNV) | Early Markers

Italy, Portugal, United Kingdom
Maximilian Stahl, MD
Syndax Pharmaceuticals

Not yet recruiting

Revumenib in Combination With 7+3 + Midostaurin in AML

Acute Myeloid Leukemia | Leukemia | AML | AML, Adult | AML With Gene Mutations

United States
Inmune Bio, Inc.

Terminated

A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Cancer | AML | MDS-EB

United Kingdom, Greece
Astellas Pharma Global Development, Inc.

No longer available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Australia, Italy, United Kingdom
Clavis Pharma

Completed

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

AML | Hematologic Malignancies

United States, United Kingdom, France, Germany, Italy, Norway
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
Carl Zeiss Meditec, Inc.
DataMed Devices Inc.

Completed

Repeatability and Reproducibility of Cirrus HD-OCT Macular Retinal Pigment Epithelium Elevation

Dry AMD With Macular Drusen

United States
Alcon Research

Terminated

Anecortave Acetate Risk-Reduction Trial (AART)

AMD

United States
Frank G. Holz
Radboud University Medical Center; Bayer; Hoffmann-La Roche; Novartis Pharmaceuticals and other collaborators

Active, not recruiting

Development of Novel Clinical Endpoints in Intermediate AMD (MACUSTAR)

Age Related Macular Degeneration (AMD)

Germany, Italy, Netherlands, United Kingdom, France, Portugal, Denmark
AbbVie
Sumitomo Pharma Oncology, Inc.

Completed

A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

United States, Germany, United Kingdom
Rubius Therapeutics

Terminated

RTX-240 Monotherapy and in Combination With Pembrolizumab

Solid Tumor, AML Adult

United States
BioSight Ltd.

Recruiting

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

AML, Adult

United States
VisionCare, Inc.

Enrolling by invitation

Post-Approval Study of the Implantable Miniature Telescope (PAS-01)

AMD

United States
Kartos Therapeutics, Inc.

Terminated

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

United States, Spain, Korea, Republic of, Belgium, United Kingdom, Hungary, France, Germany, Israel, Australia, Italy, Poland
Seattle Children's Hospital
Children's Healthcare of Atlanta; Pediatric Oncology Experimental Therapeutics...

Completed

POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients

AML | Acute Leukemia of Ambiguous Lineage | ALL | Relapsed/Refractory AML | Relapsed/Refractory ALL | Secondary AML/MDS

United States, Canada
Medical College of Wisconsin

Not yet recruiting

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed Adult AML | Refractory AML

United States
Institut de Recherches Internationales Servier
Celgene Corporation

Active, not recruiting

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS) | AML Arising From Antecedent Hematologic Disorder (AHD) | AML Arising After Exposure to Genotoxic Injury

United States, Germany, Netherlands
National Eye Institute (NEI)

Completed

Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On

Cancer | Cataract | AMD

United States
Mirati Therapeutics Inc.

Terminated

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States, Canada, United Kingdom
University of California, San Diego
Jazz Pharmaceuticals

Terminated

Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

AML | AML, Adult | Acute Myeloid Leukemia, Adult

United States
MacroGenics

Terminated

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) (VOYAGE)

AML

United States, United Kingdom, Germany, Israel, Spain, France, Italy, Netherlands
King's College Hospital NHS Trust
King's College London

Active, not recruiting

Stereotactic Radiotherapy for Wet AMD (STAR) (STAR)

Neovascular (Wet) Age-related Macular Degeneration (AMD)

United Kingdom
Washington University School of Medicine
The Leukemia and Lymphoma Society; Rising Tide Foundation; St. Louis Children...

Not yet recruiting

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML (ABCD-NK)

Acute Myeloid Leukemia | Aml | AML, Childhood | Acute Myeloid Leukemia, Pediatric

United States
Georgetown University
National Heart, Lung, and Blood Institute (NHLBI); Jazz Pharmaceuticals

Recruiting

Phase IB/II of CPX-351 for Relapse Prevention in AML

Acute Myeloid Leukemia (AML) in Remission

United States
Therapeutic Advances in Childhood Leukemia Consortium
Bristol-Myers Squibb

Active, not recruiting

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

AML, Childhood

United States
Daiichi Sankyo, Inc.

Completed

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

AML

United States, Korea, Republic of, Taiwan, United Kingdom, France, Australia, Spain, Italy, Canada, Singapore, Germany, Netherlands, Hong Kong, Belgium, Croatia, Czechia, Hungary, Poland, Serbia
Gemin X

Completed

Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)

AML

United States, Canada
AstraZeneca

Terminated

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Relapsed or Refractory Acute Myeloid Leukemia (AML)

United States
Nkarta Inc.

Active, not recruiting

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

MDS | AML, Adult | Relapsed/Refractory AML | Refractory Myelodysplastic Syndromes

United States
University of Wisconsin, Madison

Terminated

FLT-PET Imaging for MDS

AML | MDS

United States
National Eye Institute (NEI)

Active, not recruiting

Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation

AMD

United States

Clinical Trials on AMH in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations